Piper Sandler downgraded Organon & Co (OGN.US) from "Overweight" to "Underweight" and slashed its target price from $18 to $5. The move follows an audit committee investigation that uncovered significant internal control deficiencies related to the company's contraceptive product "Nexplanon," leading to misstatements in its 2022, 2024, and 2025 financial reports. On Monday, the company's stock closed down approximately 23%.

The downgrade reflects Piper Sandler's view that Organon faces a prolonged recovery, primarily due to the need to restore internal controls and investor confidence. Analysts also cautioned investors about heightened risks and volatility, given the current uncertainties and the company's challenging and lengthy turnaround process.